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Non-steroidal anti-inflammatory drugs’ anti-pyretic and anti-inflammatory effects has led some individuals to
theorize these medications may blunt core body temperature (Tc) increases during exercise. We utilized a double-
blind, randomized, and counterbalanced cross-over design to examine the effects of a 24-h naproxen dose
(3–220 mg naproxen pills) and placebo (0 mg naproxen) on Tc and plasma interleukin-6 (IL-6) concentrations
during cycling in a hot or ambient environment. Participants (n ¼ 11; 6 male, 5 female; age ¼ 27.8  6.5 years,
weight ¼ 79.1  17.9 kg, height ¼ 177  9.5 cm) completed 4 conditions: 1) placebo and ambient (Control); 2)
placebo and heat (Heat); 3) naproxen and ambient (Npx); and 4) naproxen and heat (NpxHeat). Dependent
measures were taken before, during, and immediately after 90 min of cycling and then 3 h after cycling. Overall,
Tc significantly increased pre- (37.1  0.4 C) to post-cycling (38.2  0.3 C, F1.7,67.3 ¼ 150.5, p < 0.001) and
decreased during rest (37.0  0.3 C, F2.0,81.5 ¼ 201.6, p < 0.001). Rate of change or maximum Tc were not
significantly different between conditions. IL-6 increased pre- (0.54  0.06 pg/ml) to post-exercise
(2.46  0.28 pg/ml, p < 0.001) and remained significantly higher than pre-at 3 h post- (1.17  0.14 pg/ml,
95% CI ¼ 1.01 to 0.23, p ¼ 0.001). No significant IL-6 differences occurred between conditions. A 24-h, over-
the-counter naproxen dose did not significantly affect Tc or IL-6 among males and females cycling in hot or
ambient environments.Introduction
During exercise, particularly in warm environments, working muscles
produce metabolic heat that must be dissipated to maintain a safe core
body temperature (Tc; ~37 C). Thermoregulation is controlled by the
hypothalamus, which elicits several responses to cool the body. Cardio-
vascular responses are key to thermoregulation, where peripheral vaso-
dilation and central vasoconstriction shunts warm blood from the core
and working muscles to the skin.1 Together, the cardiovascular and renal
systems regulate blood pressure and plasma volume to allow the person
to maintain their performance while also trying to dissipate metabolic
heat. When the cardiovascular system is compromised, thermoregulationdical Center, School of Health Pr
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may compromise cardiovascular function. For example, dehydration
leads to low blood pressure which stimulates fluid and sodium retention
in the kidneys and systemic vasoconstriction.1 Systemic vasoconstriction
would inhibit the person's ability to dissipate metabolic heat. In some
cases, increased Tc may cause individuals to experience exertional heat
syncope (i.e., fainting) or exhaustion (e.g., headache, dizziness). When Tc
reaches critical levels, a person can experience more serious symptoms of
exertional heat stroke (EHS).2
A life-threatening condition, EHS is characterized by severely
elevated Tc (> 40.5 C) and central nervous system dysfunction (e.g.,
aggression, loss of consciousness, irrational behavior). The critical tem-
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Abbreviations
Control Placebo and ambient condition
EHS Exertional heat stroke
GI Gastrointestinal
Heat Placebo and heat condition
HR Heart rate
IL-6 Interleukin-6
NpxHeat Naproxen and heat condition
Npx Naproxen and ambient condition
NSAID Non-steroidal anti-inflammatory drug
RH Relative humidity
Tc Core body temperature
Usg Urine specific gravity
V_O2max Maximal oxygen consumption
Table 1
Participant demographics (mean  standard deviation).
Aggregate Male Female
(n ¼ 11) (n ¼ 6) (n ¼ 5)
Age (years) 27.8  5.7 28.7  5.3 26.8  6.5
Weight (kg) 79.1  17.9 88.4  14.0 67.9  16.5
Height (cm) 177.0  9.5 183.2  5.3 169.5  7.8a
Body fat (%) 15.2  8.3 10.7  4.0 20.6  9.1b
V_O2max (mL/kg) 41.4  5.7 43.6  5.3 38.7  5.3
Abbreviations: V_O2max ¼ maximum oxygen consumption.
a Significantly less than males (F1,9 ¼ 11.856, p ¼0.007).
b Significantly greater than males (F1,9 ¼ 5.954, p ¼ 0.037).
D.M. Emerson et al. Sports Medicine and Health Science xxx (xxxx) xxxdocumented in cool environments,3 suggesting heat exposure alone is not
the cause and EHS can develop because of compromised physiological
systems. Gastrointestinal (GI) and immune system disturbances likely
drive EHS.4 In addition to metabolic heat exposure, exercise-induced
hypoxia (due to shunted blood from the GI tract) and mechanical pres-
sures damage the GI epithelial barrier.5,6 Increased GI permeability al-
lows endotoxin – gram-negative bacteria also known as
lipopolysaccharide – to leak from the GI tract into the bloodstream.4 In
healthy individuals, liver and immune responses remove circulating
endotoxin and the person can continue physical activity. If the person has
a compromised response, endotoxin builds up in the blood (i.e., endo-
toxemia) and pro-inflammatory mediators are released to neutralize the
offender. These pro-inflammatory mediators (e.g., cytokines) promote
necrosis, vasodilation, fever, decrease plasma volume, and further induce
GI damage.7–9 If unmitigated and physical activity continues, the person
may experience a systemic inflammatory response that perpetuates EHS
and/or multi-system organ failure.4
The anti-pyretic and anti-inflammatory effects of non-steroidal anti-
inflammatory drugs (NSAIDs) have led some individuals to believe these
medications may blunt Tc increases during exercise, theoretically pre-
venting exertional hyperthermia or heat illness.10 NSAIDs target cyclo-
oxygenase (COX), which is responsible for catalyzing prostaglandins
from arachidonic acid. COX-1 is inherently present in tissues throughout
the body and yields prostaglandins that regulate gastric mucosa, platelet
aggregation, and renal blood flow. COX-2 is present in small amounts and
upregulated during injury/illness by inflammatory mediators to produce
prostaglandins that promote pain, inflammation, and fever.11,12 NSAIDs
reduce fever by inhibiting the inflammatory and fever signals to the
hypothalamus.
Human and animal investigations evaluating the ability for NSAIDs to
alter Tc and inflammatory markers during exercise are limited and con-
flicting.13–15 The possibility exists that NSAIDs may compromise ther-
moregulation and exacerbate Tc increases by altering GI, liver, renal,
and/or cardiovascular functions.15–20 Among 19 ultra-marathon runners,
NSAID use was not correlated to the inflammatory cytokine interleukin-6
(IL-6) and had no effect on Tc.21 However, Tc was assessed aurally,21
which is an inaccurate Tc assessment in exercising individuals.22 Only
aspirin and ibuprofen have been evaluated in well-designed, randomized
controlled trials. The majority of investigations found that Tc did not
differ between NSAID and placebo.23–26 These investigations utilized
males and females ~20–40 years old, who exhibited a maximum aerobic
capacity (V_O2max) of ~40–65 mL/kg/min, and lean to average body fat
percentage (~10–24%). The exercise type and intensity varied consid-
erably between studies and included running, walking, or cycling for
45–60 min at set speeds, inclines, or %V_O2max.23–26 Environment also
varied between studies, ranging from cool (~18–22 C)25,26 to hot
(~40 C) temperatures. A recent investigation utilizing aspirin in older,2
less aerobically fit adults showed significant Tc increases during passive
heat exposure, compared to placebo, Tc remained higher during 120 min
of cycling in a warm environment.18 Elevated Tc was attributed to aspirin
decreasing skin blood flow, which prevented heat dissipation18; no
measures were taken to determine whether aspirin had an
anti-inflammatory effect.
NSAIDs are commonly used among the general public and physically
active persons,27–30 yet a lack of investigations examining NSAID effects
exist, particularly non-aspirin medications, on physiological responses
during exercise. As part of a larger study, we sought to determine the
acute dose effects of naproxen on Tc during exercise and assessed plasma
IL-6 to determine whether any Tc difference could be attributed to an
inflammatory mechanism. Based on NSAIDs’ potential adverse effects on
the GI tract, we hypothesized naproxen would increase Tc and plasma




Seventeen participants (12 males, 5 females) began the study; 6
participants withdrew due to difficulty, time commitment, or an unre-
lated injury. Our final sample size was 11 participants (6 male, 5 female;
demographics in Table 1). Specific information on inclusion and exclu-
sion criteria is presented in a previous publication31; briefly, participants
were free from chronic diseases, moderately endurance-trained (based on
a graded cycling V_O2max test), and were not using analgesic or
anti-inflammatory medications or treatments during the study. The study
was conducted in accordance with the Declaration of Helsinki and the
University of South Carolina's Institutional Review Board
(PRO00024476). All participants read and signed an approved informed
consent form prior to data collection.Experimental conditions
We used a double-blind, randomized and counter-balanced design.
All participants completed 4 experimental conditions: 1) placebo and
ambient (Control); 2) placebo and heat (Heat); 3) naproxen and ambient
(Npx); and 4) naproxen and heat (NpxHeat). The 24-h naproxen dose was
3 pills with 220 mg of naproxen sodium per pill. We chose this naproxen
dosage based on previous investigations examining similar 24-h NSAID
dose effects on GI and inflammatory responses.32–34 The placebo was 3
pills with 0 mg of naproxen sodium per pill. Capsules were compounded
to look the same to blind participants and primary investigators to nap-
roxen or placebo trials. Participants were randomized into a trial order
and prepared capsules in coded, sealed envelopes. We provided
take-home instructions to participants with directions for when to take
the pills – 1 pill each at 16 h, 8 h, and immediately before exercise – and
to take each pill with 8 oz of water and not with food. These instructions
were intended to maximize potential naproxen induced effects within
safe prescription guidelines. The exercise trials took place in either a hot
D.M. Emerson et al. Sports Medicine and Health Science xxx (xxxx) xxxenvironmental chamber (35.7  1.3 C, 53.2  3.2% relative humidity)
or ambient laboratory (22.7  1.8 C, 52.4  5.5% relative humidity). A
minimum of 7 days separated each experimental trial to ensure there
were no residual effects of naproxen or exercise prior to the next trial.
Instruments and protocols
Demographics
Age, sex, and height were self-reported. Weight and body fat per-
centage were measured using a bioelectrical impedance analysis scale
(Tanita SC-331S Body Composition Monitor, Tanita Co., Tokyo, Japan).
Cycle exercise protocol
During the screening session, we used the V_O2max test to familiarize
participants with the stationary cycle ergometer (Monark Ergomedic
828E, Monark Exercise AB, Vansbro, Sweden). To maintain consistency
throughout trials, seat and handlebar position were noted and the
participant used the same cycle ergometer. For each trial, participants
completed a 90-min cycle protocol. Before starting a 3-min warm-up,
researchers provided participants with their target heart rate (HR) cor-
responding to 70% V_O2max to maintain during 80 min of steady-state
cycling.35 The mean target HR for participants ¼ 125  7.1 bpm. Heart
rate was continuously monitored using Polar HR monitors (Polar Electro
Inc., Lake Success, NY). Participants were able to see the HR monitor and
researchers provided verbal cues to assist participants in maintaining HR
throughout. Following 80 min, participants cycled 10 min at maximum
effort. To encourage participants to maintain maximum effort, research
assistants gave verbal encouragement throughout the 10 min. For addi-
tional motivation, the top 5 mileages completed during the 10 min were
posted on a board in the laboratory, and researchers encouraged par-
ticipants to try to “get on the board” or beat a certain mileage. The ex-
ercise protocol ended with a 5-min cool-down.
Core temperature
We measured Tc using rectal thermometry (Doric 450 Series digital
thermometer, VAS Engineering, Inc., San Diego, CA). Participants
inserted the probe 10 cm past the anal sphincter. Baseline Tc was
assessed approximately 10 min before beginning the cycle protocol while
participants were still in an ambient environment. Participants were
continuously monitored and Tc recorded every 5 min during exercise.
Participants were not allowed to continue a trial if Tc exceeded 40 C.
The last exercise Tc measure occurred at 90 min (conclusion of the 10-
min maximum effort). Core temperature was recorded at 5 min (active
bike cool-down) and 10 min post-exercise (5-min seated cool-down).
Participants’ Tc was measured at 15 min post-exercise and then every
15 min after that during the 3-h rest period until the participant reached
baseline (pre-exercise Tc) or the rest period concluded.
Inflammatory cytokines
Blood was collected from a cubital vein pre-, post-, and 3-h post-
exercise into two 6 ml K2EDTA vacutainer tubes and inverted several
times to mix. IL-6 was assessed using enzyme linked immunosorbent
assay high sensitivity kits (R&D Systems human IL-6 Quantikine ELISA
kit, R&D Systems, Inc., Minneapolis, MN). IL-6 was chosen because IL-6 is
a prominent pro-inflammatory cytokine that induces other acute-phase
immune responses,36 and elevated IL-6 is observed in EHS patients37
and during exercise in the heat.35,38
Hydration, nutrition, and physical activity
We attempted to control factors known to affect thermoregulation
and inflammatory responses, including nutrition, hydration, and recent
physical activity. To maintain hydration during exercise, participants
drank 3.5 ml/kg of water every 15 min. Hydration status was measured
at pre-, post-, and 3-h post-exercise using urine specific gravity (Usg) by a
handheld clinical refractometer (model REF 312, Atago Company Ltd.,
Tokyo, Japan). Euhydration was defined as Usg 1.020.39 To control for3
pre-data collection dietary and physical activity influences, participants
tracked the diet and physical activity for 3 days prior and 1 day after data
collection using an online nutrition software FoodProdigy (ESHA
Research, Salem, OR). Participants were encouraged to maintain a
similar diet and physical activity habits during the 24 h prior to each data
collection session.
Procedures
Approximately 72 h before data collection, we contacted participants
with instructions to refrain from intense, vigorous exercise40 and to begin
their diet and physical activity logs. Approximately 24 h before data
collection, participants were given a sealed envelope with 2 pills and
instructions. We also reminded participants to refrain from consuming
alcohol and exercising and to maintain normal sleep behaviors. Partici-
pants were encouraged to consume fluids, such as water, to ensure
euhydration upon arriving for data collection. Lastly, we instructed
participants to consume a small meal (e.g., bagel, peanut butter and jelly)
at least 2 h before arriving to ensure no food was in the stomach.
Upon arrival at the laboratory for data collection, we verbally asked
participants if they took the 2 pills and then provided them their third
pill. We obtained a urine sample to verify participants were euhy-
drated,41 and obtained a baseline Tc and blood sample. Participants
completed the 90-min cycling bout and researchers continuously moni-
tored Tc and HR. After cycling, participants rested for 5 min where
post-blood was collected. Participants then rested for 3 h in a
semi-reclined/seated position in a laboratory set at room temperature
(23 C and 56% RH). Throughout the rest, researchers recorded Tc every
15 min. Researchers collected blood at the end of 3 h.
Statistical analysis
IBM SPSS Statistics (version XXII; IBM Corporation, Armonk, NY)
were used for all analyses. the significance level was set at p <0.05. A-
priori power calculations using standard deviations for Tc and IL-6
indicated a sample size of 8 was necessary to achieve a statistical
power of 0.8. We obtained appropriate statistical power with our
participant number (n ¼ 11), and this number is consistent with previ-
ously published research.32,35,42,43 Descriptive statistics (mean and
standard deviations) for all dependent variables were calculated. A
one-way ANOVA assessed differences in demographics (age, height,
weight, body fat %) between conditions and sex. Two repeated-measures
ANOVAs assessed Tc during exercise [4 (condition) x 20 (cycling)] and
rest [4 (condition) x 9 (rest)]. Regression analysis examined the rate of Tc
increase for each experimental condition. For IL-6, we conducted a 4
(condition) x 3 (time: pre-, post-, and 3-h post-cycling) repeatedmeasures
ANOVA. Greenhouse-Geisser corrections were used for Tc and IL-6 when
sphericity was violated. We conducted post-hoc analysis with Bonferroni
corrections on significant main effects.
Results
Table 1 presents participant demographics. Height and body fat
percentage were significantly different between sexes. Five of 6 female
participants used oral contraceptives. One participant reported a history
of exertional heat illness. All participants began experimental trials
euhydrated (Usg ¼ 1.012  0.005) and remained euhydrated to post-
(1.011  0.008) and 3 h post-exercise (1.007  0.006). As mentioned,
this study was part of a larger project; we previously reported no sig-
nificant differences between experimental conditions for hydration,
maximumHR, perceived GI symptoms (e.g., cramping, bloating, nausea),
or performance measures.31,41 Dietary analysis revealed no significant
differences in calories, protein, fats, and carbohydrates 1-day prior to
data collection. No differences were found in macronutrient intake the
morning of the trials (i.e., small meal prior to arriving) between condi-
tions. The overall morning average consumption ¼ 253.8  169.5 cal,
D.M. Emerson et al. Sports Medicine and Health Science xxx (xxxx) xxxprotein ¼ 8.2  5.5 g, fats ¼ 7.3  8.0 g, and
carbohydrates ¼ 39.8  27.6 g. Physical activity level 24-h before
remained low to sedentary and was not significantly different between
conditions. Based on maintaining a euhydrated status and the lack of
difference in hydration, nutrition, and physical activity between trials,
we are confident that Tc changes are not attributed to increased car-
diovascular strain due to hypohydration, inadequate or differences in
nutrition, or fatigue or immune responses from recent physical activity.Core temperature
Fig. 1 presents Tc changes throughout the exercise and rest for each
experimental condition. Overall, Tc significantly increased pre-
(37.1  0.4 C) to post-exercise (38.2  0.3 C, F1.7,67.3 ¼ 150.5,
p < 0.001). During rest, Tc significantly decreased over time
(F2.0,81.5 ¼ 201.6, p < 0.001) and reached baseline by 75 min post-
exercise. Starting at 60 min of cycling, mean Tc was higher in heat tri-
als compared to ambient (Fig. 1) and remained higher throughout rest.
However, no statistically significant Tc differences existed between
experimental conditions at any time point. Fig. 2a–d illustrates individual
participants’ Tc, overall mean, and regression statistics for each condi-
tion during exercise. Both Heat and NpxHeat followed a linear regression
model with no difference in slope between conditions. Similar results
were found for Tc during rest, where no significant differences in slope
between conditions were found.IL-6
We did not have complete blood data sets for 4 participants due to the
inability to complete blood collection at 3-h post-cycling. Therefore, we
present IL-6 results for 7 participants only. Differences in IL-6 between
pre-, post-, and 3-h post-exercise are presented in Fig. 3. No significant
differences were found between conditions at any time point. A signifi-
cant change in mean IL-6 occurred over time (F1.4,48 ¼ 41.8, p < 0.001),
with IL-6 increasing pre- (0.54  0.06 pg/ml) to post-exercise
(2.46  0.28 pg/ml, 95% CI ¼ 2.62 to 1.23, p <0.001) andFig. 1. Mean core body temperature during cycling and rest for experimental
(F1.7,67.3 ¼ 150.5, p < 0.001) and decrease during rest (F2.0,81.5 ¼ 201.6, p < 0.00
Control ¼ placebo and ambient environment, Heat ¼ placebo and hot environme
environment.
4
remaining significantly higher than pre-at 3-h post- (1.17  0.14 pg/ml,
95% CI ¼ 1.01 to 0.23, p ¼0.001). For each condition, post-exercise
IL-6 was significantly higher than pre- and 3 h post-cycling (Fig. 3). At 3-
h post-exercise, both Npx (1.06 0.73 pg/ml) and Heat (0.97 0.49 pg/
ml) were significantly higher compared to pre-exercise Npx
(0.44  0.29 pg/ml, 95% CI ¼ 0.05 to 1.18, p ¼ 0.038) and Heat
(0.44  0.29 pg/ml, 95% CI ¼ 0.13 to 0.93, p ¼ 0.018).
Discussion
Due to anti-pyretic and anti-inflammatory effects, some individuals
theorize NSAIDs can blunt Tc rise during exercise.10 This conjecture re-
mains unsupported by research, which in part may be explained by the
different mechanisms between exertional hyperthermia and fever.
However, it is also plausible that NSAIDs’ adverse effects on the GI tract
and cardiovascular system may negate any thermoregulatory benefit
during exercise.10 Aspirin and ibuprofen are highly accessible and used in
clinical practice; therefore, they are predominately used in scientific in-
vestigations. Naproxen, another commonly used NSAID in clinical prac-
tice, has not been investigated. We sought to determine whether a 24-h,
over-the-counter naproxen dose would affect thermoregulation and
inflammation during moderate-intense exercise. In contrast to our hy-
pothesis, naproxen had no effect on Tc or IL-6 during exercise in either an
ambient or hot environment.
Our results are consistent with findings in males administered 7.8 g of
sodium salicylate who walked in a hot environment,42 and with males
administered aspirin acutely (1.5 h pre-exercise) or chronically (daily
doses for 2 and 7 days) before walking in ambient conditions.43 These
studies42,43 and ours are in contrast to Bruning et al.,18 who showed,
compared to placebo, low dose aspirin (81 mg daily for 7 days) signifi-
cantly increased Tc during 30 min of passive heat stress.18 Increased Tc
remained significantly greater throughout 2 h of moderate-intense
cycling and was attributed to peripheral vasoconstriction that pre-
vented individuals from dissipating heat.18 Blunted skin blood flow is
understandable considering aspirin's efficacy as a cylooxygenase-1 in-
hibitor, altering vascular function and irreversibly mediating platelets.44conditions. Significant increase in core body temperature during exercise
1). No significant difference between experimental conditions. Abbreviations:
nt, Npx ¼ naproxen and ambient environment, NpxHeat ¼ naproxen and hot
Fig. 2. Regression and participant core temperature during cycling for a) Control, b) Naproxen, c) Heat, and d) Naproxen and Heat. Bold line represents mean core
temperature for condition. Shaded area indicates 10-min cycling at maximum effort. Final 5 min is an active cool down. Final Control model: ŷ ¼ 0.03x þ 37.3;
r2 ¼ 0.59; 95% CI ¼ 37.1, 37.5; p ¼ 0.001. Final Naproxen model: ŷ ¼ 0.02x þ 37.4; r2 ¼ 0.58; 95% CI ¼ 37.2, 37.6; p ¼ 0.002. Final Heat model: ŷ ¼ 0.01x þ 37.4;
r2 ¼ 0.54; 95% CI ¼ 37.2, 37.6; p < 0.001. Final Heat and Naproxen model: ŷ ¼ 0.01x þ 37.4; r2 ¼ 0.56; 95% CI ¼ 37.2, 37.6; p < 0.001.
D.M. Emerson et al. Sports Medicine and Health Science xxx (xxxx) xxxCompared to aspirin, naproxen has a greater affinity toward cyclo-
oxygenase-2,45 making naproxen more effective at reducing pain and
inflammation and less effective at mediating cardiovascular function.46
Because skin blood flow was not measured, we are unable to make a
definitive statement whether naproxen elicited any effect through pe-
ripheral vasoconstriction. Based on our lack of finding Tc changes, the
acute naproxen dosage likely does not cause skin blood flow changes.
With higher dosages (i.e., prescription strength) or longer use (i.e., 75
days), the possibility exists that we would have found a similar response
as Bruning et al.18
Our overall IL-6 increase pre-to post-exercise was expected and
similar to other scientific investigations using moderate-intense
cycling.47 Our lack of significant IL-6 changes between naproxen and
placebo is consistent with studies showing neither 1000 mg of aspirin48
nor 400 mg of ibuprofen49 significantly affected plasma inflammatory
cytokine concentrations. Ibuprofen's effects on exercise-driven
Fig. 2. (continued).
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ultra-distance running made no difference in IL-6,49 600 mg the after-
noon prior and 1200 mg on the day of an ultra-distance race resulted in
significantly higher post-race IL-6.34 We found 3–220 mg of naproxen
over 24 h prior to exercise did not significantly increase or decrease IL-6
compared to placebos. If dosing was increased and/or extended across
multiple days, a significant effect may have been found. Our relatively
large IL-6 standard deviations, particularly post-exercise among males
(Appendix A, Figure A), likely prevented us from identifying significant
effects. Skeletal muscle contraction during exercise produces a high
amount of IL-6.50 Male participants did not weigh significantly more than
females, but males had greater muscle mass, as indicated by their6
significantly lower body fat percentage (Table 1). Furthermore, partici-
pants' work output during the 10-min maximum cycling effort likely
varied. A greater muscle induced IL-6 response would be seen among
participants with more muscle mass and if they were working harder.
As previously mentioned, a Tc of 40.5 C does not necessarily trigger
EHS, and individual risk factors (e.g., medication or supplement use,
recent illness, poor cardiovascular conditioning, inadequate sleep) can
perpetuate someone experiencing EHS at a Tc < 40.5 C or in a relatively
cool environment. The complex EHS etiology requires looking at indi-
vidual variability to understand how, together, these factors may influ-
ence EHS risk. For instance, one participant, who did not use oral
contraception and was in the luteal phase when she completed the
Fig. 3. Mean interleukin-6 (IL-6) at pre-, post-, and 3 h post-cycling for experimental conditions. n ¼ 7. aSignificantly higher than pre-within condition (p < 0.04).
bSignificantly lower than post-within condition (p < 0.04). Abbreviations: Control ¼ placebo and ambient environment, Heat ¼ placebo and hot environment,
Npx ¼ naproxen and ambient environment, NpxHeat ¼ naproxen and hot environment.
D.M. Emerson et al. Sports Medicine and Health Science xxx (xxxx) xxxNpxHeat trial, experienced her highest post-exercise Tc and IL-6. This
response was not found during the luteal phase in any other female
participant. This female was also the one participant who reported a
previous exertional heat illness, had the highest body fat percentage, and
the lowest V_O2max among females. Another consideration for individual
risk factors is in the participants whowere unable to complete their trials.
A female participant during the NpxHeat trial experienced hypotension
and severe nausea; her trial was stopped. Although her pre-trial measures
were within normal limits, upon inquiry, the participant reported feeling
tired and having a GI illness within a few days before this trial. One male
participant was unable to begin a data collection trial due to extreme GI
symptoms and illness after initiating the naproxen dose; they later
withdrew from the study. These examples support the need to inquire
about NSAID use in physically active persons and educate individuals
about potential adverse events, particularly if they also present with
other known exertional heat illness risk factors.Limitations and future research
Our primary limitation was using a constant HR during 80 min of
cycling rather than using the work rate corresponding to 70% V_O2max.
Using constant HR decreased the cycling intensity during heat trials due
to cardiovascular shifts in response to thermal stress (increased HR and
blood pressure). If we had used work rate or power output corresponding
to 70% V_O2max, the increased cardiovascular strain, particularly in the
heat, would have raised Tc and increasing the difficulty to determine the
direct effects of naproxen in the different trials. While many exercise
sessions are completed at a set work rate or intensity (e.g., min per mile),
our results are useful for individuals who may use a set HR to pace
themselves during exercise. Another study limitation is only measuring
IL-6 in 7 participants, which is one less than required for appropriate
statistical power and could have prevented us from identifying signifi-
cant differences between conditions. Tumor necrosis factor-alpha is
another prominent pro-inflammatory cytokine that increases several
hours after exercise51 and would provide insight into naproxen's effects7
over the 24 h post-cycling. Another concern is the inclusion of both fe-
males who used and females who did not use oral contraception. We did
not initially control for this based on previous research showing Tc in-
creases similarly during moderate-intense exercise in the heat for both
oral contraceptive and non-oral contraceptive users.52 We also did not
initially control for the menstrual cycle phase. Post-hoc, we identified
female participant's menstrual phase for each trial, and no significant
difference existed in resting Tc in either the follicular or luteal phase. We
acknowledge the possibility that including both oral contraceptive and
non-oral contraceptive users and not conducting all trials during the
same menstrual phase (i.e., luteal) for all female participants affected our
results. Finally, despite our attempts to control certain factors (e.g.,
nutrition), we assume participants were honest with completing the diet
and physical activity logs and complying with recommendations to avoid
certain foods, medications, and activities.
Future research should examine non-aspirin NSAIDs in higher doses,
particularly evaluating prescription strength and long-term use (e.g., 14
days). We also encourage investigations that consider obtaining outcome
measures during peak plasma drug concentrations. Aspirin peaks quickly
(about 30 min) while naproxen peak plasma concentrations occur 1–3 h
after administration. We administered the last naproxen dosage
approximately 1 h before the cycling protocol began. Presumably, any
drug effect on Tc would correspond with peak concentrations, and while
it is possible our peak concentrations occurred after the exercise protocol,
we did not see a difference between trials during the 3-h rest period.
Scientific investigations are warranted in hot environments using greater
cycling intensity and other exercise modes. Running is shown to place
additional strain on the GI tract,53 which may exacerbate responses to
our various trials. Considering that GI barrier integrity is associated with
EHS models, future research should examine plasma biomarkers for
changes in GI permeability related to NSAID use and exercise in the heat.
We also suggest research on potential sex differences. Our low participant
number did not allow us to evaluate possible sex differences. Studies in
individuals with musculoskeletal injuries or compromised immune sys-
tem are also pertinent. Our study participants were non-heat
D.M. Emerson et al. Sports Medicine and Health Science xxx (xxxx) xxxacclimatized, moderately endurance trained, euhydrated, and presum-
ably had adequate nutrition and sleep prior to trials. Future in-
vestigations need to examine how individuals taking NSAIDs who are
hypohydrated, have inadequate nutrition, poor sleep, poor endurance
training, or who have other risk factors that place additional strain on
thermoregulation are affected during physical activity.
Conclusions
Our results suggest taking a 24-h naproxen dose prior to completing
moderate-intense exercise in either ambient or hot environments does
not significantly increase Tc or IL-6 in healthy, moderately endurance-
trained, euhydrated individuals. We also suggest an acute naproxen
dose before exercise does not appear to provide a thermoregulatory
benefit via an anti-pyretic or anti-inflammatory mechanism. Based on the
lack of available research in this area and well-established knowledge
that NSAIDs’ can adversely affect the cardiovascular and GI sys-
tems,18,19,32,33 we encourage physically active persons and clinicians
working with physically active populations to be conscious of the po-
tential negative effects NSAID have on thermoregulation during exercise,
particularly if the person has predisposing factors.
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Fig. A. Mean interleukin-6 (IL-6) pre-, post-, and 3 h post-cycling for a) males (n ¼ 4) and b) females (n ¼ 3). Abbreviations: Control ¼ placebo and ambient
environment, Heat ¼ placebo and hot environment, Npx ¼ naproxen and ambient environment, NpxHeat ¼ naproxen and hot environment.References
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